We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of FOLFOX4 with 'wait and go' strategy as first-line treatment for metastatic colorectal cancer.
- Authors
Kochi, Mitsugu; Ichikawa, Wataru; Meguro, Eiji; Shibata, Hiroyuki; Fukui, Takuji; Nagase, Michitaka; Hoshino, Yutaka; Takeuchi, Masahiro; Fujii, Masashi; Nakajima, Toshifusa
- Abstract
Purpose: To evaluate the efficacy and safety of FOLFOX4 using 'wait and go' strategy in treating metastatic colorectal cancer. Methods: The conventional FOLFOX4 was repeated every 2 weeks. We waited until the recovery of symptoms from persistent neurotoxicity within an added period of 2 weeks, before performing the next cycle ('wait and go' strategy). Results: We enrolled 58 patients, in whom a total of 481 cycles were administered (median 8 per patient; range 1-16). Toxicity was evaluated in 58 patients and response in 55. The major toxic effect was grade 3/4 neutropenia (33%). Painful paresthesia or persistent functional impairment was observed in 4 patients (7%). The response rate was 40% (95% confidence interval; 27.1-52.9%). The median progression-free survival time was 10.2 months, the 1-year survival rate was 89%, and the median overall survival time was 27.6 months. Conclusions: These findings indicate that this 'wait and go' strategy reduces the frequency of persistent neuropathy while maintaining efficacy against metastatic colorectal cancer.
- Subjects
COLON cancer treatment; NEUROTOXICOLOGY; NEUTROPENIA; PARESTHESIA; NEUROPATHY; OXALIPLATIN; MEDICAL statistics; METASTASIS
- Publication
Cancer Chemotherapy & Pharmacology, 2011, Vol 68, Issue 5, p1215
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-011-1605-0